Loading…
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
0pct
0d open
vs 10,940 other HR bills in the 119th — cohort avg 30d
No CRS summary is available for this bill yet. The source title, actions, sponsors, and text versions below come from Congress.gov.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Referred to the House Committee on Financial Services.
Introduced in House
Congress.gov source codes: 1000, Intro-H
Bills with similar content found using semantic analysis.
Sources: Congress.gov
2026 · third_quarter · Trade (domestic/foreign)
COINS Act Implementation; HR 9102 BINSA Bill; Importation issues; and Supply Chain Issues.
Client expense: $1,250,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · third_quarter · Trade (domestic/foreign)
CFIUS and Foreign Investment ---H.R.9102: BINSA Act ---Outbound Investment Security Program Drug Importation Drug Pricing ---CMMI: GLOBE and GUARD Models ---International Pricing Policies ---Most Favored Nation Drug Pricing Proposals ---Reference Pricing in Drug Reimbursement ---Tariffs Foreign Drug Data Protection Laws ---Implementation of BIOSECURE Act ---Implementation of COINS Global Supply Chain Resiliency Incentives for Domestic Manufacturing Intellectual Property International Enforcement Synthetic Biotech Tariffs ---General ---Section 232 Tariffs on Pharmaceuticals and Pharmaceutical Ingredients US-China Trade Relations ---H.R.9102: BINSA Act ---Implementation of COINS
Client expense: $2,560,000 · Firm income: Not reported
Government targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Natl Security Council (NSC), SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR)
2026 · third_quarter · Trade (domestic/foreign)
Proclamation: Adjusting Imports of Pharmaceuticals and Pharmaceutical Ingredients Into the United States (April 2, 2026) S. 2296: BIOSECURE Act (S.Amdt. 3236 to National Defense Authorization Act for FY 2026) S. 3452: Biological Intellectual Property Protection Act of 2025 S. 5043: Secure Drug Supply Chain Act of 2026 S. 5265: USTRx Act S. 5316: Biotech Investment National Security Act (BINSA) H.R. 4780: USTRx Act H.R. 6624: Biological Intellectual Property Protection Act of 2025 H.R. 9102: Biotech Investment National Security Act (BINSA) H.R. 9142: Prohibiting Adversarial Patents Act of 2026 (PAPA) Executive Order: Delivering Most-Favored Nation Prescription Drug Pricing to American Patients Tariff policy issues Most Favored Nation (MFN) policy issues Biopharmaceutical innovation policy issues International intellectual property and market access policy issues Pricing and reimbursement policy issues Supply chain policy issues WTO TRIPS waiver policy issues COINS Act implementation policy issues China outbound investment policy issues including COINS Act US-UK Framework Agreement
Client expense: $7,040,000 · Firm income: Not reported
2026 · third_quarter · Trade (domestic/foreign)
Proclamation: Adjusting Imports of Pharmaceuticals and Pharmaceutical Ingredients Into the United States (April 2, 2026) S. 2296: BIOSECURE Act (S.Amdt. 3236 to National Defense Authorization Act for FY 2026) S. 3452: Biological Intellectual Property Protection Act of 2025 S. 5043: Secure Drug Supply Chain Act of 2026 S. 5265: USTRx Act S. 5316: Biotech Investment National Security Act (BINSA) H.R. 4780: USTRx Act H.R. 6624: Biological Intellectual Property Protection Act of 2025 H.R. 9102: Biotech Investment National Security Act (BINSA) H.R. 9142: Prohibiting Adversarial Patents Act of 2026 (PAPA) Executive Order: Delivering Most-Favored Nation Prescription Drug Pricing to American Patients Tariff policy issues Most Favored Nation (MFN) policy issues Biopharmaceutical innovation policy issues International intellectual property and market access policy issues Pricing and reimbursement policy issues Supply chain policy issues WTO TRIPS waiver policy issues COINS Act implementation policy issues China outbound investment policy issues including COINS Act US-UK Framework Agreement
Client expense: $1,530,000 · Firm income: Not reported
2026 · third_quarter · Trade (domestic/foreign)
H.R. 9102 - Biotech Investment National Security Act (BINSA) Act: US Competitiveness, Biotechnology Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients FDA-2026-N-4699 - Expedited Investigational New Drug (IND) pilot program International Supply Chain Section 301 Investigation re: Germany Issues Foreign Freeriding Issues Non-Tariff Trade Barriers Global Health Competitiveness Issues Clinical Trial Issues
Client expense: $3,600,000 · Firm income: Not reported
Government targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Natl Economic Council (NEC), SENATE, Treasury, Dept of
Government targets: HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
Government targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
Sec. 301 pharmaceutical tariffs US-UK Framework Agreement Tariff policy issues Biopharmaceutical innovation policy issues International intellectual property and market access policy issues International pharmaceutical pricing and reimbursement policy issues Supply chain policy issues WTO TRIPS waiver policy issues China outbound investment policy issues US Swiss Trade Agreement US Trade Policy Sec. 232 pharmaceutical tariffs Pharmaceutical manufacturing policy and investment issues Outbound Investment Security Program H.R. 9102/S. 5316 - Biotech Investment National Security Act
Client expense: $840,000 · Firm income: Not reported
Government targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Patent & Trademark Office (PTO), SENATE, Treasury, Dept of, U.S. Trade Representative (USTR), White House Office
2026 · third_quarter · Health Issues
Issues related to biomanufacturing policy (H.R. 9102 / S. 5316 Biotech Investment National Security Act).
Client expense: Not reported · Firm income: $20,000
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2026 · third_quarter · Science/Technology
H.R. 2683, Remote Access Security Act, all provisions. H.R. 7625, Marine Transportation System Cybersecurity Budget and Evaluation Report (MTS CYBER) Act of 2026, all provisions. H.R. 8283, Deterring American AI Model Theft Act of 2026, all provisions. H.R. 8730, Connected Vehicle Security Act of 2026, all provisions. H.R. 9102, Biotech Investment National Security Act (BINSA), all provisions. H.R. 9129, Guarding the U.S. Against Adversarial Robotics Dominance (GUARD) Act of 2026, all provisions. H.R. 9592, American Space Leadership for the 21st Century Act, all provisions. H.R. 10670, China FIREWALL Act, all provisions. H.R. 10695, United States Submarine Cable Security Policy Act of 2026, all provisions. S. 3519, Remote Access Security Act, all provisions. S. 4429, Connected Vehicle Security Act of 2026, all provisions. S. 4939, Countering CCP Act, all provisions. S. 5316, Biotech Investment National Security Act (BINSA), all provisions. Issues Related to Adversarial Distillation of American AI Models; Chinese Biotech Industry and Dual-Use Threats; Chinese EV Manufacturing; Chinese Robotics Capabilities and Strategy; Cybersecurity Capabilities of U.S. Allies; Development of Internet Access Technologies; Information Technology Devices from Foreign Adversary Controlled Companies; Light Detection and Ranging Sensor Technology; National Guard Role in Cyber Incident Response; National Security Capabilities of Advanced AI Systems; NATO Cybersecurity Capabilities and Strategy; Securing Critical U.S. Infrastructure and Mineral Supply Chains; Securing U.S. Defense Technology; Securing U.S. Military Mobility Infrastructure; Securing U.S. Transportation Systems; TikTok Operations and Safeguards; U.S. Adversarial Use of AI and Quantum Technology; U.S. AI Chip Security; U.S. Airport Cybersecurity Enhancements; U.S. Artificial Intelligence Policy and Regulation; U.S. Cybersecurity Capabilities and Strategy; U.S. Drone Production and Market Security; U.S. Emerging Technology Capabilities, Development, and Strategy; U.S. Healthcare Cybersecurity Enhancements; U.S. Highways Cybersecurity Enhancements; U.S. Maritime Cybersecurity Enhancements; U.S. Open Technology Fund; U.S. Rail Infrastructure Cybersecurity Enhancements; U.S. Space Capabilities and Strategy; and U.S. Technology-Security Strategy (no bill).
Client expense: $210,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · third_quarter · Budget/Appropriations
FY2027 Appropriations bills; H.R.9102/S.5316, Biotech Investment National Security Act of 2026.
Client expense: Not reported · Firm income: $150,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · third_quarter · Financial Institutions/Investments/Securities
FY2027 Appropriations bills; H.R.9102/S.5316, Biotech Investment National Security Act of 2026.
Client expense: Not reported · Firm income: $150,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · third_quarter · Health Issues
FY2027 Appropriations bills; H.R.9102/S.5316, Biotech Investment National Security Act of 2026.
Client expense: Not reported · Firm income: $150,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · third_quarter · Banking
FY2027 Appropriations bills; H.R.9102/S.5316, Biotech Investment National Security Act of 2026.
Client expense: Not reported · Firm income: $150,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · third_quarter · Health Issues
Implementation of the Inflation Reduction Act of 2022, ORPHAN Cures Act (HR 946, S 1862), Mikaela Naylon Give Kids A Chance Act (HR 1262), Give Kids A Chance Act (S 932), Cameron's Law (HR 1414), Kids Access to Care Act (Accelerating HR 1509, S 752), Small Biotech Innovations Act (HR 3731, S 1930), EPIC Act (HR 1492, S 832), One Big Beautiful Bill Act (HR 1), BINSA Act, H.R. 9102, Issues related to protecting patient access to medicines in Medicare and Medicaid, Issues related to access to medicines for Parkinson's disease patients, Issues related to Antipsychotic use in Medicare, Issues related to most-favored-nation policies.
Client expense: $440,000 · Firm income: Not reported
Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
2026 · third_quarter · Trade (domestic/foreign)
BINSA Act, H.R. 9102.
Client expense: $440,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · third_quarter · Medical/Disease Research/Clinical Labs
HR 1262, S 932 Give Kids a Chance Act to renew PRV program; related provisions in H.R.1, One Big Beautiful Bill Act; HR 4709, the Newborn Screening Saves Lives Reauthorization Act; PDUFA/regulatory review process; H.R. 9102, Biotech Investment National Security Act (BINSA); H.R. 10359, Priority for Pediatric Cures Act to make PRV permanent
Client expense: $100,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2026 · third_quarter · Science/Technology
Artificial Intelligence; Research security; S.854/H.R. 1864 - Risky Research Review Act; H.R. 1048/S.1296 - the Defending Education Transparency and Ending Rogue Regimes Engaging in Nefarious Transactions (DETERRENT) Act; H.R. 9102, the Biotech Investment National Security Act of 2026
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · third_quarter · Science/Technology
Artificial Intelligence; Research security; S.854/H.R. 1864 - Risky Research Review Act; H.R. 1048/S.1296 - the Defending Education Transparency and Ending Rogue Regimes Engaging in Nefarious Transactions (DETERRENT) Act; H.R. 9102, the Biotech Investment National Security Act of 2026
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · second_quarter · Trade (domestic/foreign)
COINS Act Implementation; HR 9102 BINSA Bill; Supply Chain Issues; and Importation issues.
Client expense: $920,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · second_quarter · Trade (domestic/foreign)
CFIUS and Foreign Investment ---Outbound Investment Security Program Drug Importation Drug Pricing ---CMMI: GLOBE and GUARD Models ---International Pricing Policies ---Most Favored Nation Drug Pricing Proposals ---Reference Pricing in Drug Reimbursement ---Tariffs Foreign Drug Data Protection Laws ---A bill to prohibit contracting with certain biotechnology providers, and for other purposes. ---Implementation of BIOSECURE Act ---Implementation of COINS Global Supply Chain Resiliency Incentives for Domestic Manufacturing Intellectual Property International Enforcement ---China Synthetic Biotech Tariffs Trade Relations ---Section 232 US-China Trade Relations ---H.R.9102: BINSA Act ---Implementation of COINS ---IP Provisions World Health Organization (WHO) ---WHO Pandemic Preparedness Accord
Client expense: $2,360,000 · Firm income: Not reported
Government targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Security Council (NSC), SENATE, Treasury, Dept of, White House Office
2026 · second_quarter · Trade (domestic/foreign)
Proclamation: Adjusting Imports of Pharmaceuticals and Pharmaceutical Ingredients Into the United States (April 2, 2026) S. 2296: BIOSECURE Act (S.Amdt. 3236 to National Defense Authorization Act for FY 2026) H.R. 4780: USTRx Act H.R. 6089: Biomanufacturing Excellence Act of 2025 H.R. 9102: Biotech Investment National Security Act of 2026 (BINSA) H.R. 9142: Prohibiting Adversarial Patents Act of 2026 (PAPA) Executive Order: Delivering Most-Favored Nation Prescription Drug Pricing to American Patients Tariff policy issues Most Favored Nation (MFN) policy issues Biopharmaceutical innovation policy issues International intellectual property and market access policy issues Pricing and reimbursement policy issues Supply chain policy issues WTO TRIPS waiver policy issues COINS Act implementation policy issues China outbound investment policy issues including COINS Act US-UK Framework Agreement
Client expense: $7,360,000 · Firm income: Not reported
Government targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE, Treasury, Dept of
Sec. 301 pharmaceutical tariffs US-UK Framework Agreement Tariff policy issues Biopharmaceutical innovation policy issues International intellectual property and market access policy issues International pharmaceutical pricing and reimbursement policy issues Supply chain policy issues China outbound investment policy issues US Swiss Trade Agreement US Trade Policy Sec. 232 pharmaceutical tariffs Pharmaceutical manufacturing policy and investment issues Outbound Investment Security Program H.R. 9102 - Biotech Investment National Security Act
Client expense: $1,410,000 · Firm income: Not reported
Government targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Patent & Trademark Office (PTO), SENATE, Treasury, Dept of, U.S. Trade Representative (USTR), White House Office
2026 · second_quarter · Science/Technology
H.R. 4142, No Adversarial AI Act, all provisions. H.R. 6309, Cyber Deterrence and Response Act of 2025, all provisions. H.R. 7037, Developing Overseas Mineral Investments and New Allied Networks for Critical Energies (DOMINANCE) Act, all provisions. H.R. 7625, Marine Transportation System Cybersecurity Budget and Evaluation Report (MTS CYBER) Act of 2026, all provisions. H.R. 7924, Trucking Security and CCP Disclosure Act of 2026, all provisions. H.R. 8516, American Leadership in AI Act, all provisions. H.R. 8558, Defending American Research Act, all provisions. H.R. 8730, Connected Vehicle Security Act of 2026, all provisions. H.R. 9102, Biotech Investment National Security Act (BINSA), all provisions. H.R. 9129, Guarding the U.S. Against Adversarial Robotics Dominance (GUARD) Act of 2026, all provisions. H.R. 9227, Magnets Value Chain Support Act of 2026, all provisions. H.R. 9592, American Space Leadership in the 21st Century Act, all provisions. S. 4429, Connected Vehicle Security Act of 2026, all provisions. S. 4525, Securing Innovation and Research from Adversaries Act, all provisions. S. 4565, Strengthening Cyber Resilience Against State-Sponsored Threats Act, all provisions. S. 4570, U.S. Tech Path Act, all provisions. Issues Related to Chinese Biotech Industry and Dual-Use Threats; Chinese Cellular Modules; Chinese EV Manufacturing; Chinese Robotics Capabilities and Strategy; Chinese Unmanned Aerial Systems; Chinese, Iranian, and Russian Cyber Operations; Chinese-Made Battery Storage Systems; CISA Resourcing; Cyber-Informed Engineering; Cybersecurity Capabilities of U.S. Allies; Development of Internet Access Technologies; Information Technology Devices from Foreign Adversary-Controlled Companies; Light Detection and Ranging Sensor Technology; National Guard Role in Cyber Incident Response; Securing Critical U.S. Infrastructure and Mineral Supply Chains; Securing U.S. Defense Technology; Securing U.S. Military Mobility Infrastructure; Securing U.S. Transportation Systems; U.S. Adversarial Use of AI and Quantum Technology; U.S. AI Chip Security; U.S. Airport Cybersecurity Enhancements; U.S. Artificial Intelligence Policy; U.S. Cybersecurity Capabilities and Strategy; U.S. Data Security Capabilities and Strategy; U.S. Drone Production and Market Security; U.S. Emerging Technology Capabilities, Development, and Strategy; U.S. Fusion Energy Development; U.S. Healthcare Cybersecurity Enhancements; U.S. Highways Cybersecurity Enhancements; U.S. Maritime Cybersecurity Enhancements; U.S. Nuclear Energy Capabilities; U.S. Quantum Technology Capabilities; U.S. Rail Infrastructure Cybersecurity Enhancements; U.S. Space Capabilities and Strategy (no bill).
Client expense: $240,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · second_quarter · Trade (domestic/foreign)
H.R. 9102 - Biotech Investment National Security Act (BINSA) Act: US Competitiveness, Biotechnology H.R. 4930 - To Expand the Sharing of Information with Respect to Suspected Violations of Intellectual Property Rights in Trade International Supply Chain Section 301 Investigation re: Germany Issues Market Access Most Favored Nation Policies Foreign Freeriding Issues Non-Tariff Trade Barriers Competitiveness Issues Trade Issues
Client expense: $1,880,000 · Firm income: Not reported
Government targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, U.S. Trade Representative (USTR)
2026 · second_quarter · Health Issues
Implementation of the Inflation Reduction Act of 2022, ORPHAN Cures Act (HR 946, S 1862), Mikaela Naylon Give Kids A Chance Act (HR 1262), Give Kids A Chance Act (S 932), Cameron's Law (HR 1414), Kids Access to Care Act (Accelerating HR 1509, S 752), Small Biotech Innovations Act (HR 3731, S 1930), EPIC Act (HR 1492, S 832), One Big Beautiful Bill Act (HR 1), BINSA Act, H.R. 9102, Issues related to protecting patient access to medicines in Medicare and Medicaid, Issues related to access to medicines for Parkinson's disease patients, Issues related to Antipsychotic use in Medicare, Issues related to most-favored-nation policies.
Client expense: $700,000 · Firm income: Not reported
Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
2026 · second_quarter · Trade (domestic/foreign)
BINSA Act, H.R. 9102.
Client expense: $700,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · second_quarter · Budget/Appropriations
FY2027 Appropriations bills; H.R. 9102, Biotech Investment National Security Act of 2026.
Client expense: Not reported · Firm income: $130,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · second_quarter · Banking
FY2027 Appropriations bills; H.R. 9102, Biotech Investment National Security Act of 2026.
Client expense: Not reported · Firm income: $130,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · second_quarter · Financial Institutions/Investments/Securities
FY2027 Appropriations bills; H.R. 9102, Biotech Investment National Security Act of 2026.
Client expense: Not reported · Firm income: $130,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · second_quarter · Health Issues
FY2027 Appropriations bills; H.R. 9102, Biotech Investment National Security Act of 2026.
Client expense: Not reported · Firm income: $130,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · second_quarter · Science/Technology
Monitored and advised on Artificial Intelligence; Monitored S.854/H.R. 1864 - Risky Research Review Act; Monitored H.R. 1048/S.1296 - the Defending Education Transparency and Ending Rogue Regimes Engaging in Nefarious Transactions (DETERRENT) Act; Monitored and advised on H.R. 9102, the Biotech Investment National Security Act of 2026.
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · second_quarter · Medical/Disease Research/Clinical Labs
HR 1262, S 932 Give Kids a Chance Act to renew PRV program; related provisions in H.R.1, One Big Beautiful Bill Act; HR 4709, the Newborn Screening Saves Lives Reauthorization Act; PDUFA/regulatory review process; H.R. 9102, Biotech Investment National Security Act (BINSA)
Client expense: $140,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2026 · second_quarter · Defense
Issues related to H.R. 9102 - Biotech Investment National Security Act of 2026 (BINSA).
Client expense: Not reported · Firm income: $80,000
Government targets: HOUSE OF REPRESENTATIVES
2026 · second_quarter · Trade (domestic/foreign)
Proclamation: Adjusting Imports of Pharmaceuticals and Pharmaceutical Ingredients Into the United States (April 2, 2026) S. 2296: BIOSECURE Act (S.Amdt. 3236 to National Defense Authorization Act for FY 2026) H.R. 4780: USTRx Act H.R. 9102: Biotech Investment National Security Act (BINSA) H.R. 9142: Prohibiting Adversarial Patents Act of 2026 (PAPA) Executive Order: Delivering Most-Favored Nation Prescription Drug Pricing to American Patients Tariff policy issues Most Favored Nation (MFN) policy issues Biopharmaceutical innovation policy issues International intellectual property and market access policy issues Pricing and reimbursement policy issues Supply chain policy issues WTO TRIPS waiver policy issues COINS Act implementation policy issues China outbound investment policy issues including COINS Act US-UK Framework Agreement
Client expense: $890,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)